Antivirals for the treatment of chronic hepatitis B: Current and future options

Intervirology

Volumn 46, Issue 6, 2003, Pages 413-420

  Humphries, Jason C ^a   Dixon, Jonathan S ^b  

^a Development and Medical Affairs Division   (Japan)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Drug therapy; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FUTUROLOGY; HEPATITIS B; HUMAN; LIVER FUNCTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; SURVIVAL ANALYSIS; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 0346156070     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075001     Document Type: Conference Paper

References (44)

1. Davey S: State of the World's Vaccines and Immunization. Geneva, World Health Organisation, 1996, pp 76-82.
2. Gust ID: Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996;38:S18-23.
3. Fattovich G: Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 1998;45:1206-1213.
4. Lok AS: Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992;10:46-52.
5. Mast EE, Alter HJ: Epidemiology of viral hepatitis: An overview. Semin Virol 1993;4:273-283.
6. Tanaka R, Itoshima T, Nagashima H: Follow-up study of 582 liver cirrhosis patients for 26 years in Japan. Liver 1987;7:316-324.
7. Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956.
8. Sarin SK, Chari S, Sundaram KR, Ahuja RK, Anand BS, Broor SL: Young v adult cirrhotics: A prospective, comparative analysis of the clinical profile, natural course and survival. Gut 1988;29:101-107.
9. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M: A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
10. Liaw YF, Lin DY, Chen TJ, Chu CM: Natural course after the development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Liver 1989;9:235-241.
11. Sankaranarayanan R, Black RJ, Parkin DM: Population-based cancer survival: An analysis of 16,922 cases. Chin J Oncol 1998;20:202-206.
12. Lok AS, Lai CL, Wu PC, Lau JY, Leung EK, Wong LS, Fung YL: Alpha-interferon treatment in Chinese patients with chronic hepatitis B. J Hepatol 1990;11:S121-125.
13. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, Sampliner R, Feit D, Lefkowitch J, Kuhns M, Meschievitz C, Sanghvi B, Albrecht J, Gibas A: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323:295-301.
14. Hoofnagle JH, di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
15. Lee WM: Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
16. Schiff ER, Sorrell MF, Maddrey WC: Diseases of the Liver, ed 8. Hagerstown, Lippincott Williams & Wilkins, 1999.
17. Jarvis B, Faulds D: Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999;58:101-141.
18. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Carithers R, Rustgi V, Di Bisceglie A, Balan V, Murray A, Rooney J, Jaffe HS: Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled phase II studies (abstract). Hepatology 1998;28:317A.
19. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart C: Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 weeks preliminary analysis (abstract). Hepatology 2002;36:374A.
20. Farrell GC: Clinical potential of emerging new agents in hepatitis B. Drugs 2000;60:701-710.
21. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
22. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER: Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-117.
23. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM: Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B (abstract). J Gastroenterol Hepatol 2001;16:S16.
24. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 2001;33:1527-1532.
25. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E: Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-755.
26. Pil HS, Kwang-Hyub H, Hoon AS, Han PY, Yoon CC, Myoung MY: Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endemic area (abstract). Hepatology 2001;34:322A.
27. Liaw YF, Leung N, Guan R, Lau GK, Merican I: Asian-Pacific consensus statement on the management of chronic hepatitis B: An update. J Gastroenterol Hepatol 2003;18:239-245.
28. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ: Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
29. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.
30. Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, Merigan TC, Gregory PB: Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984;101:613-616.
31. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-1635.
32. Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E, Lim SG: Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002;16:1939-1944.
33. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, de Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-826.
34. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
35. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999;29:889-896.
36. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-568.
37. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816.
38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-807.
39. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C, Poynard T: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study. Lancet 2001;358:718-723.
40. Yang H, Westland CE, Delaney WET, Heathcote EJ, Ho V, Fry J, Brosgart C, Gibbs CS, Miller MD, Xiong S: Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-473.
41. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, de Man RA, Goodman Z, Condreay LD, Crowther LM, Woessner MA, McPhillips PJ, Brown NA: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-826.
42. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306.
43. Willems B, Lau G, Leung N, Schiff E, Trepo C, Wright T, Watkins K, Woessner M, Brosgart C, Bourne E, Tait D: Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine: 52 week results (abstract). Antivir Ther 2002;7:L111.
44. Mutimer D, Hann HWL, Buti M, Strasser S, Watkins K, Woessner M, Brosgart C, Bourne E, Tait D, Perrillo R: Safety and efficacy of adding adefovir dipivoxil to lamivudine in decompensated patients with YMDD variants and a reduced response to lamivudine - One year results (abstract). Antivir Ther 2002;7:L90.